You are here: Industry Insights > AveXis

News List

Catalent’s Harmans Site Approved to Manufacture AveXis’ Gene Therapy contractpharma
August 10, 2020
To produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy gene therapy at its manufacturing facility in Harmans, MD.
Novartis’ AveXis agrees to manufacture US researcher Covid-19 vaccine pharmaceutical-technology
June 01, 2020
Novartis unit AveXis has entered a manufacturing agreement with researchers at Massachusetts Eye and Ear and Massachusetts General Hospital in the US to produce a genetic vaccine against Covid-19, AAVCOVID.
AveXis Enters Mfg. Pact for Novel Genetic COVID-19 Vax contractpharma
May 29, 2020
AAVCOVID, being developed by U.S. researchers in Massachusetts, leverages adeno-associated viral vector technology to produce immunity.
Novartis inks deal to make Mass General Brigham’s COVID-19 vaccine candidate expresspharma
May 29, 2020
AveXis, which makes Novartis’s $2.1 million-per-patient gene therapy Zolgensma for the hereditary disease spinal muscular atrophy, is contributing technology, expertise and its manufacturing supply chain at no cost.
AveXis Receives EC Approval, Activates “Day One” Access Spinal Muscular Atrophy Gene Therapy americanpharmaceuticalreview
May 26, 2020
AveXis, a Novartis company, announced the European Commission (EC) granted conditional approval for Zolgensma® (onasemnogene abeparvovec) ...
Novartis firm AveXis gets EC nod for Zolgensma to treat spinal muscular atrophy pharmaceutical-business-review
May 21, 2020
Novartis company AveXis has secured conditional approval from the European Commission (EC) for its Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA).
Novartis’ AveXis gets EC conditional approval for Zolgensma pharmaceutical-technology
May 20, 2020
Novartis subsidiary AveXis has received conditional approval from the European Commission (EC) for Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA).
AveXis’ Zolgensma gene therapy yields desired results in SMA trials pharmaceutical-business-review
March 27, 2020
AveXis said that a one-time infusion of Zolgensma (onasemnogene abeparvovec-xioi) delivered rapid, substantial, and clinically meaningful therapeutic benefit ...
Ousted AveXis execs doctored Zolgensma data themselves fiercepharma
September 26, 2019
Former AveXis CSO Brian Kaspar, in a previous statement from law firm Heuston Hannigan, “categorically denies any wrongdoing,” and said he is “prepared to assert his rights and defend his conduct accordingly.” And contradicting AveXis’ description, he sai
Novartis to put AveXis into protective custody after data manipulation scandal fiercepharma
September 26, 2019
The Swiss drugmaker says not only will AveXis’ quality team be folded into its organization, it will happen as quickly as possible.

Previous page 1 2 3 Next page